• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Volitinib

Volitinib

Product ID V574451
Cas No. 1313725-88-0
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $106.40 In stock
5 mg $170.40 In stock
25 mg $476.90 In stock
100 mg $1,342.30 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Volitinib is an inhibitor of c-Met. It shows antitumor potential in models of gastric cancer. It is being investigated as a treatment for papillary renal cell carcinoma, where it has demonstrated an acceptable tolerability profile.

Product Info

Cas No.

1313725-88-0

Purity

≥98%

Formula

C17H15N9

Formula Wt.

345.37

Chemical Name

Volitinib

IUPAC Name

1-[(1S)-1-(Imidazo[1,2-a]pyridin-6-yl)ethyl]-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine

Synonym

Savolitinib, HMPL 504, HMPL0-504, HMPL504, AZD-6094, AZD 6094, AZD6094

Solubility

Insoluble in water. Solubility in DMSO - ~15 mg/mL.

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

V574451 MSDS PDF

Info Sheet

V574451 Info Sheet PDF

References

Gavine P., Ren Y., et al. Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models. Mol Oncol. 9(1):323-33 (2015). PMID: 25248999.

Gan H., Millward M., et al. First-in-Human Phase I Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics and Anti-Tumor Activity. Clin Cancer Res. 2019. PMID: 30952639.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • I7359

    1-Isothiocyanato-8-(methylsulfenyl)-octane

    ITC, erucin analog.

    ≥98%
  • M4200

    MK-0752

    γ-Secretase inhibitor.

    ≥98%
  • A4853

    β-Amyloid Peptide (1-42), human

    Endogenous APP peptide cleavage product, primar...

    ≥95%
  • M0125

    Magnolol

    Lignan found in Magnolia; GABA-A potentiator.

    ≥98%
  • O8500

    Ovalbumin Fragment (257-264)

    OVA antigen.

    ≥98%
  • D0262

    Dapiprazole Hydrochloride

    α1-Adrenergic antagonist.

    ≥98%
  • S164098

    Seco-rapamycin

    Rapamycin analog

    ≥73%
  • C2965

    Chromium Picolinate

    Used to prevent chromium deficiency and to decr...

    ≥98%
  • D6957

    Droloxifene

    Triphenylthylene, tamoxifen analog; SERM.

    ≥98%
  • C691325

    Cridanimod

    STING agonist

    ≥99%
  • A5282

    [Sar1 Ile8]-Angiotensin II

    Peptide, derivative of AT II, involved in vasoc...

    ≥95%
  • P0109

    P7C3A20

    Fluorinated aminopropyl carbazole, neuroprotect...

    ≥94%
  • V3277

    Vitamin E

    Synthetic vitamin E, antioxidant.

    ≥98%
  • M177521

    Menaquinone-7

    2-methyl-1,4-naphthoquinone derivative

    98%
  • R0154

    Ranolazine Dihydrochloride

    Nav1.7 and Nav1.8 N1+ channel blocker.

    ≥98%
  • K624760

    KPT-276

    CRM1/XPO1 inhibitor.

    ≥99%
  • N8663

    NVP-LDE225 Diphosphate

    Smo inhibitor.

    ≥98%
  • C1621

    CEF4

    Peptide, vSrc-induced cytokine.

    ≥95%
  • E6257

    Epothilone B

    Microtubule depolymerization inhibitor.

    ≥98%
  • S0831

    S-(−)-Schisandrin B

    Found in Schisandra.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only